Castro SC, Santos RA, Salazar RJC, Díaz RI, Góngora BR, González MP

Language: Spanish
References: 29
Page: 8-15
PDF size: 171.37 Kb.

ABSTRACT

Background: Lipodystrophy syndrome in HIV-infected patients receiving antiretroviral therapy is characterized by loss of peripheral subcutaneous adipose tissue and increase of central adipose tissue.
Objective: To determine the prevalence of lipodystrophy syndrome in a group of HIV-infected patients who receive antiretroviral therapy, at Yucatan, Mexico.
Material and method: Prospective, observational, descriptive and cross-sectional study over 123 patients with at least one year of antiretroviral therapy at Hospital General Agustín O’Horan. To collect its clinical and demographic data, it was applied a questionnaire to each patient. Anthropometric measurement in their skin folds (cheek, biceps, triceps, and femur) was made, and BMI and the waist/hip index were calculated.
Results: Prevalence of lipodystrophy syndrome was 16%, 5% with hypertrophy, 40% with atrophy and 55% with a mixed pattern. Presence of lipodystrophy syndrome was associated to the duration of the antiretroviral therapy.
Conclusion: Prevalence of lipodystrophy syndrome, present in Yucatan’s patients, was lower to that reported in other countries. Anthropometry offers a low-cost alternative to diagnose this disease.

REFERENCES

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients whit advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-60.

2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(7):F51-8.

3. Garg A. Lipodystrophies. Am J Med 2000;108(2):143-52.

4. Mauss S. HIV-associated lipodystrophy syndrome. AIDS 2000;14(supp 13):S197-207.

5. Carr A, Samaras K, Chisholm D, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;351(9119):1881-3.

6. Qaqish RB, Rublein J, Wohl DA. HIV-associated lipodystrophy syndrome. Pharmacotherapy 2000;20(1):13-22.

7. Carr A, Miller J, Law M, Cooper D. A syndrome of lipoatrophy, lactic academia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitorrelated lipodystrophy syndrome. AIDS 2000;14(15):F25-32.

8. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviraltherapy- related lipodystrophy. Lancet 1999;354(9184):1112-5.

9. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving longterm nucleoside analogue therapy. AIDS 1999;13(13):1659-67.

10. Galli M, Veglia F, Angarano G, et al. Metabolic and morphological alterations under antiretroviral therapy: preliminary results of Lipodystrophy Italian Multicentre Study (LIMS). Abstracts of the Fifth International Congress on Drug Therapy in HIV Infection. AIDS 2000;14(suppl 4):S54. Abstract P133.

11. Galli M, Cozzi-Lepri A, Ridolfo AL, et al. Incidence of adipose alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Inter Med 2002;162(22):2621-8.

12. Collazos J, Rodríguez-Guardado A, Maradona JA, et al. Factors influencing the development of lipodystrophy in human immunodeficiency virus-infected patients. Scand J Infect Dis 2003;35(5):339-40.

13. Guaraldi G, Murri R, Orlando G, et al. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clin Trials 2003;4(2):99-106

14. Worm D, Kirk O, Andersen O, et al. Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance. HIV Med 2002;3(4):239-46.

15. Ávila-Rosas H, Tejero-Barrera E. Evaluación del estado de nutrición. En: Casanueva E, Kaufer-Horwitz M, Pérez-Lizaur AB, Arroyo P, eds. Nutriología médica. 2ª ed. México: Panamericana, 2001;pp:594-669.

16. Fundación Mexicana para la Salud AC. Obesidad, consenso. 1ª ed. México: Mc Graw-Hill-Interamericana, 2002;pp:2-8.

17. Chávez-Ballado G. Distribución de tejido adiposo de acuerdo a Síndrome de lipodistrofia en pacientes con infección por VIH que reciben tratamiento antirretroviral edad, sexo y ocupación en una población Yucateca. TESIS, México: Escuela Nacional de Antropología e Historia, 1995;pp:43-44.

18. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Inmune Defic Syndr 2002;31(1):50-5.

19. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003;4(3):293-301

20. Avilés-Cobián R, Pavía-Ruz NM, Muños-Hernández MR, Arellano-Montaño SA, Cardiel-Marmolejo L, Sánchez-García AG. Síndrome de lipodistrofia en niños y adolescentes. Abstracts del XLIII Congreso Nacional de la Sociedad Mexicana de Endocrinología y Nutrición. Revista de endocrinología y nutrición 2003.

21. Paton NI, Earnest A, Ng YM, Karim F, Aboulhab J. Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact. Clin Infect Dis 2002;35(10):1244-9.

22. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Inmune Defic Syndr 2003;34(1):58-61.

23. Martínez E, Gatell JM. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome. Curr Opin Infect Dis 1999;12(1):13-9.

24. Engelson ES, Kotler DP, Tan YX, et al. Fat distribution in HIVinfected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 1999;69(6):1162-9.

25. Mallon PW, Miller J, Cooper D, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003;17(7):971-9.

26. Thiébaut R, Daucourt V, Mercié P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitane Cohort, France, 1999. Groupe d’Epidémiologie Clinique du Syndrome d’Immunodéficience Acquise en Aquitaine. Clin Infect Dis 2000;31(6):1482-7.

27. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003;17(10):1503-11.

28. Martínez E, Mocroft A, García-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357(9256):592-8.

29. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002;16(18):2447-54.